Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

During a recent press conference, Trump stated that he would not rule out using military or economic force to acquire ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

At the moment, the hottest GLP-1 treatment is Ozempic. Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications including Wegovy ...

Credit: Andrey_Popov via Shutterstock. Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most ...